Clearside Biomedical is a biopharmaceutical company focused on vision treatments for people with serious back of the eye diseases. Co.'s proprietary SCS Microinjector targeting the suprachoroidal space, or SCS, provides access to the macula, retina and choroid where sight-threatening disease often occurs. Co.'s SCS injection platform is a non-surgical procedure intended to provide targeted delivery to the site of disease and to work with formulations of medications, as well as therapeutic treatment. Co. is utilizing its SCS injection platform by building an internal research and development pipeline targeting retinal diseases and by creating external collaborations with other companies. The CLSD stock yearly return is shown above.
The yearly return on the CLSD stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CLSD annual return calculation with any dividends reinvested as applicable (on ex-dates).
|